Ascites Clinical Trials

33 recruitingLast updated: June 18, 2026

There are 33 actively recruiting ascites clinical trials across 20 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Guangzhou, Guangdong, China, Jena, Germany, Berlin, Germany. Updated daily from ClinicalTrials.gov.


Ascites Trials at a Glance

33 actively recruiting trials for ascites are listed on ClinicalTrialsFinder across 6 cities in 20 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Guangzhou, Jena, and Berlin. Lead sponsors running ascites studies include Aleksander Krag, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), and Abramson Cancer Center at Penn Medicine.

Treatments under study

About Ascites Clinical Trials

Looking for clinical trials for Ascites? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ascites trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ascites clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting

QOL and Sarcopenia in Patients With Ascites

Ascites, MalignantAscites Hepatic
Abramson Cancer Center at Penn Medicine70 enrolled1 locationNCT05726747
Recruiting
Not Applicable

Free Fluid Detection With Telementored eFAST

AscitesPostoperative ComplicationsHemoperitoneum+1 more
Oslo University Hospital40 enrolled1 locationNCT06594562
Recruiting
Not Applicable

Early TIPS in Patients With Liver Cirrhosis and Ascites

Liver CirrhosisPortal HypertensionAscites Hepatic
University Hospital Freiburg134 enrolled1 locationNCT06576934
Recruiting
Phase 4

Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis

CirrhosisAscitesPortal Vein Thrombosis+3 more
Asian Institute Of Medical Sciences220 enrolled1 locationNCT07521332
Recruiting
Phase 1Phase 2

Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites

AscitesOvarian Neoplasms Malignant
Cancer Institute and Hospital, Chinese Academy of Medical Sciences29 enrolled1 locationNCT07435701
Recruiting
Phase 2

Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis

CirrhosisDecompensated Cirrhosis of LiverDecompensated Liver Cirrhosis+1 more
CAMC Health System50 enrolled1 locationNCT06764966
Recruiting
Phase 1Phase 2

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Malignant ascites
Dong sheng Zhang48 enrolled1 locationNCT07397819
Recruiting
Phase 3

Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites

Decompensated Cirrhosis and Ascites
Aleksander Krag240 enrolled12 locationsNCT05056220
Recruiting
Early Phase 1

A Clinical Study of GK02 in Malignant Ascites

Malignant Ascites Caused by Advanced Solid Tumors
Beijing Geekgene Technology Co., LTD9 enrolled1 locationNCT07378436
Recruiting
Not Applicable

Underdilated-stent Technique Improves Post-TIPS Encephalopathy

Liver CirrhosisAscites HepaticVariceal Bleeding, Cirrhosis+1 more
The Second Affiliated Hospital of Chongqing Medical University72 enrolled2 locationsNCT07349654
Recruiting
Not Applicable

Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension

Portal Hypertension Related to CirrhosisVariceal BleedingAscites Hepatic
C. R. Bard166 enrolled1 locationNCT06669806
Recruiting

Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China

AscitesAbdominal NeoplasmAbdominal Injury
The Children's Hospital of Zhejiang University School of Medicine108 enrolled1 locationNCT07113808
Recruiting
Phase 1Phase 2

Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites

Ascites, MalignantCancer of Stomach, Adenocarcinoma
Qilu Hospital of Shandong University24 enrolled1 locationNCT06759064
Recruiting
Phase 2

High Dose Albumin in Refractory Ascites

Ascites
Baylor College of Medicine100 enrolled1 locationNCT05867602
Recruiting

VICIS - Vienna Cirrhosis Study

AscitesLiver CirrhosisPortal Hypertension+2 more
Medical University of Vienna10,000 enrolled1 locationNCT03267615
Recruiting

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Pleural Effusion, MalignantAscites, MalignantCarcinoma+4 more
Travera Inc200 enrolled1 locationNCT05461430
Recruiting
Phase 1

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

Cirrhosis, LiverLiver FibrosisAscites Hepatic
PharmaIN74 enrolled9 locationsNCT05490888
Recruiting
Not Applicable

Kinesio-Taping vs. Usual Care for Malignant Bowel Obstruction With Ascites

Advanced CancerAscitesMalignant Bowel Obstruction
National Taiwan University Hospital40 enrolled1 locationNCT07023042
Recruiting
Phase 1

A Phase I Study of SIM0388 in Participants With Malignant Ascites.

Malignant ascites
Jiangsu Simcere Pharmaceutical Co., Ltd.50 enrolled1 locationNCT07007988
Recruiting
Phase 1

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Malignant Pleural EffusionMalignant ascites
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)12 enrolled1 locationNCT06016179